NCT00961779 - Safety Study of NNZ-2566 in Healthy Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions

Brain Injuries, Traumatic

Interventions

DRUG

NNZ-2566

Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.

DRUG

Placebo

Normal saline infusion

Trial Locations (1)

3004

Nucleus Network, Melbourne